Treatment-for-prevention: Clinical considerations

Current Opinion in HIV and AIDS

Volumn 7, Issue 2, 2012, Pages 131-139

  Lockman, Shahin ^a   Sax, Paul ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

adherence; antiretroviral treatment; clinical benefit; HIV; resistance; risk compensation; test and treat; toxicity; treatment for prevention

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; PLACEBO; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DRUG INTOXICATION; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857371278     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834fcf6b     Document Type: Review

References (65)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505. This paper describes the first randomized trial to assess a preferred CD4 threshold at which to initiate ART, among patients with CD4 350 cells/ml (albeit as a secondary endpoint, as heterosexual transmission of HIV to HIV-serodiscordant partners constituted the primary endpoint).
2. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
3. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2011. [Epub ahead of print] In this analysis, among HIV-infected men-who-have-sex-with-men in a well resourced setting with extensive access to ART and healthcare, and assuming HIV diagnosis relatively early in disease progression (median CD4 count at diagnosis 432 cells/ml), the projected median life-expectancy was 75 years. Therefore, on average, 7 years of life were lost because of HIV (comparable with the effect of cigarette smoking).
4. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209-216.
5. Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4 cell count thresholds <200 <350 and <500 cells/mm3: assessment of need following changes in treatment guidelines. Clin Infect Dis 2011; 53:817-825. The estimated median times from seroconversion to CD4 count less than 500, less than 350, and less than 200 cells/ml were 1.10, 4.19, and 7.93 years, respectively, in a European cohort. One of the strengths of this analysis lies in the fact that the date of HIV seroconversion was known with some degree of accuracy, permitting more reliable estimate of time to disease progression.
6. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
7. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4 cell strata. Ann Intern Med 2003; 138:620-626.
8. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257-265. This paper describes the first randomized trial to assess a preferred CD4 threshold at which to initiate ART, among patients with CD4 greater than 200 cells/ml. It is also among the first to provide data on this topic from a resource-limited setting, in which ART was generally initiated at CD4 less than 200 cells/ml (and in which the epidemiology of HIV-associated illnesses such as tuberculosis differs considerably from that in well resourced settings).
9. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in ntiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144. (Pubitemid 351590049)
10. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157-166.
11. World Health Organization Press. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva; 2010.
12. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197. (Pubitemid 46763289)
13. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
14. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171:1560-1569. This recent study was unique among observational 'when to start' analyses, as it was able to reduce the potential for lead time bias as the investigators had access to reasonably well characterized HIV seroconversion dates. The analysis also used a unique analytic approach, creating sequential nested subcohorts rather than using marginal structural models.
15. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 10 January 2011. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 13 October 2011].
17. Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One 2008; 3:e2021.
18. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
19. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
20. Mellors JW, Margolick JB, Phair JP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 2007; 297:2349-2350. (Pubitemid 46883761)
21. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
22. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4 cell count. JAMA 1998; 279:35-40. (Pubitemid 28070548)
23. Mugavero MJ, Napravnik S, Cole SR, et al. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011; 53:927-935. A novel analysis examining (after ART start) 'viremia copy-years' (as a measure o cumulative plasma HIV-1 burden) as a potential predictor and driver of cumulative inflammation and immune system activation among patients.
24. Reekie J, Gatell J, Yust I, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. AIDS 2011;25(18):2259-68. This analysis of data from a large prospective cohort adds to the growing body of evidence suggesting that higher levels of HIV-1 RNA are associated with disease progression, even among patients with higher (and similar) CD4 cell count.
25. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009; 14:1065-1074.
26. Choi AI, Shlipak MG, Hunt PW, et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23:2143-2149.
27. McCune JM. The dynamics of CD4 T-cell depletion in HIV disease. Nature 2001; 410:974-979. (Pubitemid 32335848)
28. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371. (Pubitemid 44924494)
29. Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110:1133-1139. (Pubitemid 35215894)
30. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55:615-619.
31. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-447.
32. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747-1751.
33. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50:1056-1063.
34. Verma S, Goldin RD, Main J. Hepatic steatosis in patients with HIV-hepatitis C virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis? BMC Res Notes 2008; 1:46.
35. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009; 15:552-558.
36. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
37. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl. 1):S21-S33. (Pubitemid 37158630)
38. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB10101 and abrogated by low CD4 T-cellcounts. AIDS 2005; 19:97-99. (Pubitemid 40111026)
39. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. (Pubitemid 46658704)
40. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:281-288.
41. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330. An updated analysis using prospective data from more than 33 000 patients (accruing nearly 179 000 patient years of follow-up) of the association between different antiretrovirals and myocardial infarction (MI). This analysis permitted assessment of the association between tenofovir and MI (none found).
42. Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011; 12:157-165.
43. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir- ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
44. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir preexposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011; 6:e23688.
45. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505. A systematic review and meta-analysis of data from prospective studies with comparative design and systematic reporting of renal outcomes, which found statistically significantly more (but clinically modest) decline in renal function with tenofovir vs. other antiretrovirals, as well as a higher risk of acute renal injury.
46. Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009; 10:343-355.
47. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
48. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599. This paper describes the first published randomized trial of the use of prophylactic antiretrovirals (TDF/FTC) for preventing heterosexual transmission of HIV. A 44% reduction in HIV acquisition was observed (95% CI 15-63, P0.005).
49. Thigpen M, Kebaabetswe P, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Abstract # WELBC01. 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy; 2011.
50. Baeten J. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study. HIV-1- infected adults. Abstract MOAX0106. Paper presented at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011; Rome, Italy.
51. Mugavero MJ, May M, Ribaudo HJ, et al. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr 2011; 58:253-260.
52. Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2010; 54:197-203.
53. Bastard M, Koita Fall MB, Laniece I, et al. Revisiting long-term adherence to HAART in Senegal using latent class analysis. J Acquir Immune Defic Syndr 2011;57(1):55-61. This study from Senegal presents adherence data over a long period of time from a resource limited setting, and demonstrates decreasing adherence with time.
54. Uy J, Armon C, Buchacz K, et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51:450-453.
55. Lodi S, Kuchner C, Kran A. Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection. Presentation O114. Paper presented at Tenth International Congress on Drug Therapy in HIV Infection (HIV10) 2010; Glasgow, UK.
56. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S. AIDS 2010; 24:1203-1212.
57. Aghokeng AF, Kouanfack C, Laurent C, et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 2011; 25:2183-2188.
58. Kasang C, Kalluvya S, Majinge C, et al. HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One 2011; 6:e23091.
59. Hamers RL, WallisCL, KityoC, et al. HIV-1 drug resistance in antiretroviralnaive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
60. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203:1174-1181.
61. Kelly JA, Hoffman RG, Rompa D, Gray M. Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex. AIDS 1998; 12:F91-F95. (Pubitemid 28302411)
62. Tun W, Gange SJ, Vlahov D, et al. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIVinfected injection drug users. Clin Infect Dis 2004; 38:1167-1174. (Pubitemid 38951266)
63. Brennan DJ, Welles SL, Miner MH, et al. HIV treatment optimism and unsafe anal intercourse among HIV-positive men who have sex with men: findings from the positive connections study. AIDS Educ Prev 2010; 22:126-137.
64. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
65. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656. (Pubitemid 46281312)